Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.61 |
| ▸ | AGXT | P21549 | 2/20 | 0.61 |
| ▸ | APP | P05067 | 5/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL153642 | 0.81 | IDO1 (0.61) | IDO1AGXTAPPCA12CA1 | |
| SCHEMBL31270 | 0.80 | IDO1 (0.67) | IDO1AGXTAPPCA12CA1 | |
| SCHEMBL34413 | 0.80 | IDO1 (0.67) | IDO1AGXTAPPCA12CA1 | |
| SCHEMBL1475481 | 0.78 | IDO1 (0.64) | IDO1AGXTAPPCA12CA1 | |
| SCHEMBL20000873 | 0.78 | APP (0.80) | IDO1AGXTAPPMAOBHTT | |
| Potassium SCHEMBL1477050 | 0.78 | IDO1 (0.64) | IDO1AGXTAPPCA12CA1 | |
| SCHEMBL18459071 | 0.77 | IDO1 (0.57) | IDO1AGXTAPPCA12CA1 | |
| SCHEMBL23872341 | 0.76 | IDO1 (0.61) | IDO1AGXTAPPCA12CA1 | |
| SCHEMBL21588833 | 0.76 | IDO1 (0.61) | IDO1AGXTAPPCA12CA1 | |
| SCHEMBL1520099 | 0.76 | IDO1 (1.00) | IDO1AGXTAPPMAOBTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744209-B2 | Biodegradable polymeric nanoparticle conjugates and use thereof | NEW YORK UNIVERSITY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20180339063-A1 | BIODEGRADABLE POLYMERIC NANOPARTICLE CONJUGATES AND USE THEREOF | NEW YORK UNIVERSITY | 2018-11-29 | — | — | US | disclosed |
| US-8604036-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| US-20110034474-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-10 | — | — | US | disclosed |
| WO-2007008541-A2 | CELLULAR CHOLESTEROL ABSORPTION MODIFIERS | KALYPSYS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| EP-1020459-B1 | CIS-DISUBSTITUTED AMINOCYCLOALKYL-PYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
| EP-0641795-B9 | CARBAPENEM DERIVATIVE | DAIICHI SEIYAKU CO (JP) | 2003-01-29 | — | — | EP | disclosed |
| EP-0641795-B1 | CARBAPENEM DERIVATIVE | DAIICHI SEIYAKU CO (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-20020077345-A1 | Cis-substituted aminocycloalkylpyrrolidine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. | 2002-06-20 | — | — | US | disclosed |
| EP-0790982-B1 | METHODS OF SYNTHESIS OF PEPTIDYL ARGININALS | CORVAS INT INC (US) | 2002-02-27 | — | — | EP | disclosed |
| US-5514777-A | Methods of synthesis of peptidyl argininals | CORVAS INTERNATIONAL, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1995035280-A1 | METHODS OF SYNTHESIS OF PEPTIDYL ARGININALS | CORVAS INTERNATIONAL, INC. (US) | 1995-12-28 | — | — | WO | disclosed |
| WO-1995026968-A1 | TRINUCLEAR CATIONIC PLATINUM COMPLEXES HAVING ANTITUMOUR ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1995-10-12 | — | — | WO | disclosed |
| EP-0641795-A1 | CARBAPENEM DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| EP-0618225-A1 | Linear adhesion inhibitors | MERCK PATENT GmbH (DE) | 1994-10-05 | — | — | EP | disclosed |
| EP-0608215-A1 | QUINOBENZOXAZINE, QUINOBENZOTHIAZINE, AND PYRIDO-ACRIDINE ANTINEOPLASTIC AGENTS | ABBOTT LABORATORIES (US) | 1994-08-03 | — | — | EP | disclosed |
| WO-1994005681-A1 | NEW ACETALS OF KETOPHOSPHAMIDES AND ALKYLGLYCOSIDES | BAYER AG (DE) | 1994-03-17 | — | — | WO | disclosed |
| EP-0608215-A4 | QUINOBENZOXAZINE, QUINOBENZOTHIAZINE, AND PYRIDO-ACRIDINE ANTINEOPLASTIC AGENTS. | ABBOTT LAB (US) | 1993-11-11 | — | — | EP | disclosed |
| WO-1992003136-A1 | QUINOBENZOXAZINE, QUINOBENZOTHIAZINE, AND PYRIDO-ACRIDINE ANTINEOPLASTIC AGENTS | ABBOTT LABORATORIES (US) | 1992-03-05 | — | — | WO | disclosed |
| EP-0363320-A2 | Substituted 9H purine | CIBA-GEIGY AG (CH) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339063-A1 | BIODEGRADABLE POLYMERIC NANOPARTICLE CONJUGATES AND USE THEREOF | CD47, SLC46A1, ABCB1 | IDO1 3183/4885AGXT 2647/4885APP 915/4885 |
| US-20110034474-A1 | PYRIDAZINONE DERIVATIVES | MET, ERBB2, BRAF | IDO1 983/4885AGXT 2391/4885APP 4653/4885 |
| US-10744209-B2 | Biodegradable polymeric nanoparticle conjugates and use thereof | CD47, SLC46A1, ABCB1 | IDO1 3183/4885AGXT 2647/4885APP 915/4885 |
| US-20020077345-A1 | Cis-substituted aminocycloalkylpyrrolidine derivatives | Q6ZSR9, ARG1, ASNS | IDO1 1777/4885AGXT 2194/4885APP 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.